Home Cart Sign in  
Chemical Structure| 1268524-70-4 Chemical Structure| 1268524-70-4

Structure of (+)-JQ1
CAS No.: 1268524-70-4

Chemical Structure| 1268524-70-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

(+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomains (BRD4(1/2)). It also activates autophagy.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Chrysanthi Kagiou ; Jose A. Cisneros ; Jakob Farnung ; Joanna Liwocha ; Fabian Offensperger ; Kevin Dong , et al.

Abstract: Targeted degradation (TPD) relies on small molecules to recruit proteins to E3 ligases to induce their ubiquitylation and degradation by the . Only a few of the approximately 600 human E3 ligases are currently amenable to this strategy. This limits the actionable target space and clinical opportunities and thus establishes the necessity to expand to additional ligases. Here we identify and characterize SP3N, a specific degrader of the prolyl isomerase FKBP12. SP3N features a minimal design, where a known FKBP12 ligand is appended with a flexible alkylamine tail that conveys degradation properties. We found that SP3N is a precursor and that the alkylamine is metabolized to an active aldehyde species that recruits the SCFFBXO22 ligase for FKBP12 degradation. Target engagement occurs via covalent adduction of Cys326 in the FBXO22 C-terminal domain, which is critical for ternary complex formation, ubiquitylation and degradation. This mechanism is conserved for two recently reported alkylamine-based degraders of NSD2 and XIAP, thus establishing alkylamine tethering and covalent hijacking of FBXO22 as a generalizable TPD strategy.

Purchased from AmBeed:

Alternative Products

Product Details of (+)-JQ1

CAS No. :1268524-70-4
Formula : C23H25ClN4O2S
M.W : 456.99
SMILES Code : O=C(OC(C)(C)C)C[C@H]1C2=NN=C(C)N2C3=C(C(C)=C(C)S3)C(C4=CC=C(Cl)C=C4)=N1
MDL No. :MFCD22683748
InChI Key :DNVXATUJJDPFDM-KRWDZBQOSA-N
Pubchem ID :46907787

Safety of (+)-JQ1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Related Pathways of (+)-JQ1

epigenetics

Isoform Comparison

Biological Activity

Target
  • BET

    BRD4 (2), IC50:33 nM

    BRD4 (1), IC50:77 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
ARP-1 0.5 μM 72 h JQ1 upregulated the expression of MICA in ARP-1 cells. J Hematol Oncol. 2016 Dec 1;9(1):134.
JJN3 0.5 μM 72 h JQ1 upregulated the expression of MICA in JJN3 cells. J Hematol Oncol. 2016 Dec 1;9(1):134.
U266 0.5 μM 72 h JQ1 upregulated the expression of MICA in U266 cells. J Hematol Oncol. 2016 Dec 1;9(1):134.
RPMI-8226 0.5 μM 72 h JQ1 upregulated the expression of MICA in RPMI-8226 cells. J Hematol Oncol. 2016 Dec 1;9(1):134.
Adult rat ventricular fibroblasts (ARVFs) 10μM to 5nM 72 h JQ1 inhibited TGF-β1-stimulated α-SMA signal with an IC50 of 94nM. Circ Res. 2019 Sep 13;125(7):662-677.
Adult rat ventricular fibroblasts (ARVFs) 500nM 72 h JQ1 significantly reduced basal and TGF-β-mediated collagen gel contraction and profoundly reduced α-SMA protein expression. Circ Res. 2019 Sep 13;125(7):662-677.
KP-4 cells 500 nM 9 h JQ1 increased LC3II levels, indicating that JQ1 activates autophagy by inhibiting BRD4 Mol Cell. 2017 May 18;66(4):517-532.e9.
NMC 797 cells 500 nM 48 h JQ1 induces differentiation in NMC cells, characterized by changes in cell morphology and increased keratin expression Nature. 2010 Dec 23;468(7327):1067-73.
U2OS cells 500 nM JQ1 competitively binds to BRD4, leading to its displacement from nuclear chromatin as demonstrated by FRAP experiments Nature. 2010 Dec 23;468(7327):1067-73.
SKO-007(J3) 0.5 μM 72 h JQ1 upregulated the expression of MICA in SKO-007(J3) cells, enhancing their sensitivity to NK cell-mediated cytotoxicity. J Hematol Oncol. 2016 Dec 1;9(1):134.
cortical neurons 250 nM 10 min JQ1 pretreatment blocked the rapid induction of Arc, Fos, and Nr4a1 after TTX withdrawal Nat Neurosci. 2015 Oct;18(10):1464-73.
cortical neurons 250 nM 10 min JQ1 pretreatment blocked the BDNF-induced increase in transcription of Arc, Fos, and Nr4a1 Nat Neurosci. 2015 Oct;18(10):1464-73.
C2C12 cells 200 nM 24 h JQ1 treatment prevented H2O2-induced oxidative stress, restored LC3II abundance, and reduced p62 levels. Nat Commun. 2020 Nov 30;11(1):6108.
H2081 cells 1 µM 48 h JQ1 significantly reduced ASCL1 and IGFBP5 expression, while having no effect on IGFBP3 expression. Nat Commun. 2019 Jul 19;10(1):3201.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NMC 797 xenograft model Intraperitoneal injection 50 mg/kg Once daily for 4 days JQ1 significantly reduces tumor growth, induces keratin expression, and inhibits tumor proliferation Nature. 2010 Dec 23;468(7327):1067-73.
Mice Adult male mice Intraperitoneal injections 50 mg/kg Daily for one week or three weeks JQ1 treatment affected memory formation and decreased seizure susceptibility in mice Nat Neurosci. 2015 Oct;18(10):1464-73.
Mice Mdx mouse model Intraperitoneal injection 20 mg/kg Once daily for two weeks JQ1 treatment reduced muscle damage and inflammation in mdx mice, improving muscle function. Nat Commun. 2020 Nov 30;11(1):6108.
Mice ASCL1High SCLC xenograft model Intraperitoneal injection 25 mg/kg Every other day, continuous treatment Combination treatment of JQ1 and BMS-754807 significantly inhibited tumor growth, while monotherapy with either JQ1 or BMS-754807 had limited effects. Nat Commun. 2019 Jul 19;10(1):3201.
Nude mice Xenograft mouse models Intraperitoneal injection 50 mg/kg 5 days a week, continuous treatment To evaluate the resistance of SPOP-mutant tumors to BET inhibitor JQ1, results showed that SPOP-mutant tumors were resistant to JQ1 treatment Nat Med. 2017 Sep;23(9):1063-1071
Mouse Cardiomyocyte-specific BRD4 knockout mouse Intraperitoneal injection 50mg/kg Once daily for 2 weeks To evaluate the effect of JQ1 on cardiac function, it was found that JQ1-treated hearts did not affect baseline cardiac function but showed protective effects in the pathological hypertrophy model. Circulation. 2020 Dec 15;142(24):2356-2370
Zebrafish Hepatocyte ablation model Water treatment 3 μM From A12h to R6h To study the role of BET proteins in liver regeneration, it was found that JQ1 treatment temporarily inhibited liver regeneration, but regeneration resumed after washout. J Hepatol. 2016 Feb;64(2):316-325.
Zebra fish Transgenic zebra fish expressing human 0N/4R-Tau Bath exposure 2 μM Continuous exposure from 2 to 5 days To evaluate the effects of (+)JQ1 on motor function, survival, microgliosis, and synaptic elimination in Tau zebra fish. Results showed that (+)JQ1 improved hypokinesia, increased survival, reduced microgliosis, and prevented brain synapse elimination. Nat Commun. 2024 Sep 18;15(1):8195
C57BL/6J mice Oxidative stress-induced retina degeneration model Intraperitoneal injection 50 mg/kg Daily for 3 days JQ1 inhibited SI-induced cGAS-STING activation, reduced retina inflammation and degeneration, and improved retinal integrity. Cell Death Differ. 2022 Sep;29(9):1816-1833
Mice Myc-Cap model Intraperitoneal injection 50 mg/kg Daily, continuous treatment To test the combined effect of JQ1 with anti-CTLA-4 immunotherapy, results showed that the combination significantly increased the CD8/Treg ratio and demonstrated a potential survival benefit. J Immunother Cancer. 2019 Oct 25;7(1):277
Mouse Fancd2−/− mice Intraperitoneal injection 50 mg/kg Daily for 1 month Reduce DNA damage in LT-HSC, improve survival Cell Stem Cell. 2021 Jan 7;28(1):33-47. e8
NSG mice HCC70 xenograft model Intraperitoneal injection and oral gavage 50 mg/kg Once daily for 21 days Evaluate the anti-tumor effect of JQ1 in combination with BEZ235, showing significant reduction in tumor volume and suppression of K14 expressing cell shift Nat Commun. 2018 Sep 19;9(1):3815

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.19mL

0.44mL

0.22mL

10.94mL

2.19mL

1.09mL

21.88mL

4.38mL

2.19mL

References

 

Historical Records

Categories